Category: Press Releases
Loving Parents Plan a 15,000 mile Journey of Hope in Memory of their Daughter
Home / Blog / [wpbb post:title] Dave Fleischer, a volunteer and supporter of the Cholangiocarcinoma Foundation (CCF), plans to spend…
CCF Celebrates FDA’s Filing Acceptance and Priority Review of TIBSOVO® for the Treatment of IDH1-mutations in CCA
Home / Blog / [wpbb post:title] On behalf of patients and families impacted by cholangiocarcinoma (CCA), the Cholangiocarcinoma Foundation (CCF)…
CCF Awards $300,000 in Research Grants to Fund Early Career Investigators at Renowned Institutions
Home / Blog / [wpbb post:title] The Cholangiocarcinoma Foundation (CCF), a nonprofit organization funding novel research for bile duct cancer…
CCF Presents First-Ever Poster Awards
Home / Blog / [wpbb post:title] The Cholangiocarcinoma Foundation (CCF) announced the inaugural 2021 Poster Abstract Awards at its virtual…
CCF is pleased to award the 2021 Mark R. Clements Award to Renuka Iyer and Lisa Craine
Home / Blog / [wpbb post:title] The Mark R. Clements award for Vision, Innovation and Collaboration is the highest honor…
Cholangiocarcinoma Foundation Hails Milestone in Effort to Advance new Treatment for IDH1-positive Cholangiocarcinoma Patients as Agios Announces New FDA Filing for TIBSOVO®
On behalf of patients and families impacted by cholangiocarcinoma (CCA), the Cholangiocarcinoma Foundation (CCF) today hailed progress in the development…
Cholangiocarcinoma Foundation partners with Japan Cholangiocarcinoma Association to Increase Global Advocacy for Bile Duct Cancer
Cholangiocarcinoma Foundation (CCF), the largest cholangiocarcinoma advocacy organization in the world, has partnered with the newly formed Japan Cholangiocarcinoma Association…
Cholangiocarcinoma Foundation Celebrates 15th Anniversary Milestone
FDA Approves Incyte's Pemazyre™ (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma…
Cholangiocarcinoma Foundation Launches Trusted Partners Program
FDA Approves Incyte's Pemazyre™ (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma…
Cholangiocarcinoma Foundation celebrates FDA’s Breakthrough Therapy Designation for Zanidatamab in Patients with Biliary Tract Cancer
The Cholangiocarcinoma Foundation (CCF) celebrates the November 30, 2020 FDA breakthrough therapy designation for Zanidatamab in patients with previously-treated HER2…